p.109 抽出テキスト

September 25, 2018 Circulation. 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 e380

CLINICAL STATEMENTS AND GUIDELINES cardiomyopathy: impact and recognition of epicardial origin. J Cardiovasc Electrophysiol. 2016;27:709–17. S9-12.	 Hasdemir C, Ulucan C, Yavuzgil O, et al. Tachycardia-induced car-

diomyopathy in patients with idiopathic ventricular arrhythmias: the incidence, clinical and electrophysiologic characteristics, and the predictors. J Cardiovasc Electrophysiol. 2011;22:663–8. S9-13.	 Kanei Y, Friedman M, Ogawa N, et al. Frequent premature ventricular complexes originating from the right ventricular outflow tract are associated with left ventricular dysfunction. Ann Noninvasive Electrocardiol. 2008;13:81–5. S9-14.	 Kawamura M, Badhwar N, Vedantham V, et al. Coupling interval dispersion and body mass index are independent predictors of idiopathic premature ventricular complex-induced cardiomyopathy. J Cardiovasc Electrophysiol. 2014;25:756–2. S9-15.	 Niwano S, Wakisaka Y, Niwano H, et al. Prognostic significance of frequent premature ventricular contractions originating from the ventricular outflow tract in patients with normal left ventricular function. Heart. 2009;95:1230–7. S9-16.	 Olgun H, Yokokawa M, Baman T, et al. The role of interpolation in PVC-induced cardiomyopathy. Heart Rhythm. 2011;8:1046–9. S9-17.	 Yokokawa M, Good E, Crawford T, et al. Recovery from left ventricular dysfunction after ablation of frequent premature ventricular complexes. Heart Rhythm. 2013;10:172–5. S9-18.	 Zhong L, Lee YH, Huang XM, et al. Relative efficacy of catheter ablation vs antiarrhythmic drugs in treating premature ventricular contractions: a single-center retrospective study. Heart Rhythm. 2014;11:187–93. S9-19.	 Deyell MW, Park KM, Han Y, et al. Predictors of recovery of left ventricular dysfunction after ablation of frequent ventricular premature depolarizations. Heart Rhythm. 2012;9:1465–72. S9-20.	 Kubac G, Klinke WP, Grace M, Randomized double blind trial com-

paring sotalol and propranolol in chronic ventricular arrhythmia. Can J Cardiol. 1988;4:355–9.

10 VA AND SCD RELATED TO SPECIFIC

POPULATIONS

10.1 Athletes

S10.1-1.	 Zipes DP, Link MS, Ackerman MJ, et al. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 9: arrhythmias and conduction defects: a scientific statement from the American Heart Association and American College of Cardiology. Circulation. 2015;132:e315–28. S10.1-2.	 Biffi A, Pelliccia A, Verdile L, et al. Long-term clinical significance of frequent and complex ventricular tachyarrhythmias in trained athletes. J Am Coll Cardiol. 2002;40:446–52. S10.1-3.	 Verdile L, Maron BJ, Pelliccia A, et al. Clinical significance of exercise-induced ventricular tachyarrhythmias in trained athletes without cardiovascular abnormalities. Heart Rhythm. 2015;12:78–85. S10.1-4.	 Harmon KG, Asif IM, Maleszewski JJ, et al. Incidence, cause, and comparative frequency of sudden cardiac death in national collegiate athletic association athletes: a decade in review. Circulation. 2015;132:10–9. S10.1-5.	 Maron BJ, Haas TS, Ahluwalia A, et al. Incidence of cardiovascular sudden deaths in Minnesota high school athletes. Heart Rhythm. 2013;10:374–7. S10.1-6.	 Harmon KG, Drezner JA, Wilson MG, et al. Incidence of sudden cardiac death in athletes: a state-of-the-art review. Br J Sports Med. 2014;48:1185–92. S10.1-7.	 Marijon E, Tafflet M, Celermajer DS, et al. Sports-related sudden death in the general population. Circulation. 2011;124:672–81. S10.1-8.	 Meyer L, Stubbs B, Fahrenbruch C, et al. Incidence, causes, and survival trends from cardiovascular-related sudden cardiac arrest in children and young adults 0 to 35 years of age: a 30-year review. Circulation. 2012;126:1363–72. S10.1-9.	 Marijon E, Bougouin W, Perier MC, et al. Incidence of sportsrelated sudden death in France by specific sports and sex. JAMA. 2013;310:642–3. S10.1-10.	 Anderson JH, Tester DJ, Will ML, et al. Whole-exome molecular

autopsy after exertion-related sudden unexplained death in the young. Circ Cardiovasc Genet. 2016;9:259–65. S10.1-11.	 Bagnall RD, Weintraub RG, Ingles J, et al. A prospective study of

sudden cardiac death among children and young adults. N Engl J Med. 2016;374:2441–52. S10.1-12.	 Semsarian C, Ingles J, Wilde AA, Sudden cardiac death in the young: the molecular autopsy and a practical approach to surviving relatives. Eur Heart J. 2015;36:1290–6. S10.1-13.	 Maron BJ, Haas TS, Ahluwalia A, et al. Demographics and epidemiology of sudden deaths in young competitive athletes: from the United States national registry. Am J Med. 2016;129:1170–7. S10.1-14.	 Yankelson L, Sadeh B, Gershovitz L, et al. Life-threatening events during endurance sports: is heat stroke more prevalent than arrhythmic death? J Am Coll Cardiol. 2014;64:463–9. S10.1-15.	 Maron BJ, Haas TS, Murphy CJ, et al. Incidence and causes of sudden death in US college athletes. J Am Coll Cardiol. 2014;63: 1636–43. S10.1-16.	 Link MS, Myerburg RJ, Estes NA 3rd. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 12: emergency action plans, resuscitation, cardiopulmonary resuscitation, and automated external defibrillators: a scientific statement from the American Heart Association and American College of Cardiology. Circulation. 2015;132:e334–8. S10.1-17.	 Brothers JA, Frommelt MA, Jaquiss RDB, et al. Expert consensus guideline: anomalous aortic origin of a coronary artery – American Association for Thoracic Surgery Clinical Practice Guidelines. J Thorac Cardiovasc Surg. 2017;153:1440–57. S10.1-18.	 Van Hare GF, Ackerman MJ, Evangelista JA, et al. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 4: congenital heart disease: a scientific statement from the American Heart Association and American College of Cardiology. Circulation. 2015;132:e281–9. S10.1-19.	 Ackerman MJ, Zipes DP, Kovacs RJ, et al. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 10: the cardiac channelopathies: a scientific statement from the American Heart Association and American College of Cardiology. Circulation. 2015;132:e326–91. S10.1-20.	 Maron BJ, Udelson JE, Bonow RO, et al. Eligibility and disqualifica-

tion recommendations for competitive athletes with cardiovascular abnormalities: Task Force 3: Hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and other cardiomyopathies, and myocarditis: a scientific statement from the American Heart Association and American College of Cardiology. Circulation. 2015;132:e273–80.

10.2 Pregnancy

S10.2-1.	 Seth R, Moss AJ, McNitt S, et al. Long QT syndrome and pregnancy. J Am Coll Cardiol. 2007;49:1092–8. S10.2-2.	 Jeejeebhoy FM, Zelop CM, Lipman S, et al. Cardiac arrest in pregnancy: a scientific statement from the American Heart Association. Circulation. 2015;132:1747–73. S10.2-3.	 Vanden Hoek TL, Morrison LJ, Shuster M, et al. Part 12: cardiac arrest in special situations: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2010;122 suppl 3:S829–61. S10.2-4.	 Natale A, Davidson T, Geiger MJ, et al. Implantable cardioverterdefibrillators and pregnancy: a safe combination? Circulation. 1997;96:2808–12. S10.2-5.	 Colletti PM, Lee KH, Elkayam U, Cardiovascular imaging of the pregnant patient. Am J Roentgenol. 2013;200:515–21. S10.2-6.	 Khositseth A, Tester DJ, Will ML, et al. Identification of a common genetic substrate underlying postpartum cardiac events in congenital long QT syndrome. Heart Rhythm. 2004;1:60–4. S10.2-7.	 Rashba EJ, Zareba W, Moss AJ, et al. Influence of pregnancy on the risk for cardiac events in patients with hereditary long QT syndrome. LQTS Investigators. Circulation. 1998;97:451–6. S10.2-8.	 Heradien MJ, Goosen A, Crotti L, et al. Does pregnancy increase cardiac risk for LQT1 patients with the KCNQ1-A341V mutation? J Am Coll Cardiol. 2006;48:1410–5. S10.2-9.	 Davis RL, Eastman D, McPhillips H, et al. Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy. Pharmacoepidemiol Drug Saf. 2011;20:138–45. S10.2-10.	 Ruys TP, Maggioni A, Johnson MR, et al. Cardiac medication during

pregnancy, data from the ROPAC. Int J Cardiol. 2014;177:124–8.

Downloaded from http://ahajournals.org by on October 7, 2026